Table 1.

Effect of maternal anti–β3 integrin IgG and IVIG on fetal and neonatal bleeding disorders




Breeding cages

Total pups

Dead pups

Bleeding disorders

Miscarriage*
First delivery      
   β3–/– × WT  7   57   2#  0**  0  
   Immunized β3–/– × WT  8   54   13#††  7**  2  
   Immunized β3–/– × WT; IVIG§  2   12  0  0   0  
Second delivery      
   Immunized β3–/– × WT; IVIG  5   36   1††  2‡‡  0  
   Immunized β3–/– × WT albumin
 
2
 
16
 
1
 
4‡‡
 
0
 



Breeding cages

Total pups

Dead pups

Bleeding disorders

Miscarriage*
First delivery      
   β3–/– × WT  7   57   2#  0**  0  
   Immunized β3–/– × WT  8   54   13#††  7**  2  
   Immunized β3–/– × WT; IVIG§  2   12  0  0   0  
Second delivery      
   Immunized β3–/– × WT; IVIG  5   36   1††  2‡‡  0  
   Immunized β3–/– × WT albumin
 
2
 
16
 
1
 
4‡‡
 
0
 

Underlined value indicates that statistically significant difference was also observed compared with the immunized but IVIG-untreated group in the first delivery (χ2 > 4.13; P < .05).

*

Female β3–/– mice delivered immature dead pups

Naive female β3–/– mice (without immunization with WT platelets) were bred with WT male mice

Female β3–/– mice; first delivery after two times immunization with WT platelets

§

Female β3–/– mice were transfused with IVIG during first delivery

Female β3–/– mice were transfused with IVIG during second delivery

Female β3–/– mice were transfused with albumin as a control during second delivery

#

P < .005. This and the following three footnotes indicate P values for comparisons of the two values in the table sharing that footnote

**

P < .005

††

P < .05

‡‡

P < .05

Close Modal

or Create an Account

Close Modal
Close Modal